

**Keywords:** Human breast cancer; Breast malignancy; Vascular disease

## Introduction

1.4 million Reports of women having breast cancer had been projected in 2008 [1]. In all most important region of the world, breast malignancy is the Commonest, or second commonest, cancer in women [2]. Now breast cancer is everywhere in the world. High-income, westernized, industrialized countries have the widespread problem of breast cancer. ere is notable increase in life expectation in people of least-income levels in many countries and the augmented propensity to accept a westernized way of life, on the basis of that cancer is a rapidly growing global problem [3]. Of course, in the above statements, 'cancer' could be Same as 'vascular disease' or 'chronic obstructive pulmonary disease' or 'diabetes' or any number of chronic situations coupled with aged populations adopting a westernized lifestyle. Today, every woman

---

through a cellulose acetate membrane (pore diameter 0.45  $\mu$ m). Maintain the solution under vacuum, while swirling the filtration unit, until no additional bubbles are produced in the solution. Add appropriate amounts of ammonium persulfate solution and TEMED swirl and transfer immediately into the gap between the two glass plates of the mould. Leave adequate space for the stacking gel (the length of the teeth of the comb plus 1 cm). Using a tapered glass pipette carefully overlay the solution with water-saturated isobutanol. Leave the gel in a vertical position at room temperature to allow polymerisation.

**Staining/destaining:** Dip the gel in a large overload *staining solution* and permit to stand for at least 1 h. Eradicate the staining solution. Destain the gel with a large excess of destaining solution. Change the de

to check reappearance by blocking the estrogen receptors on breast cancer cells and preventing estrogen from binding to them.

A class of drugs called aromatase inhibitors essentially stops estrogen production in post-menopausal women. Women who have not yet gone through menopause cannot take these drugs.

#### References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 127: 2893-2917.
2. Curado MP, Edwards BK, Shin HR, Ferlay J, Storm H (2009) *Cancer Incidence in Five Continents, Volume IX*. Lyon, France: IARC Press.
3. Boyle P, Levin B (2008) *World Cancer Report 2008*. IARC Press, Lyon, France.
4. Platet N, Prévostel C, Derocq D, Joubert D, Rochefort H, et al. (1998) Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. *Int J Cancer* 75: 750-756.
5. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, et al. (2007) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. *J Cell Physiol* 150: 534-544.
6. Fuqua SA, Cui Y (2004) Estrogen and progesterone receptor isoforms: clinical implications. *Endocr Rev* 25: 1-12.
7. Price JE, Polyzos A, Zhang RD, Daniels LM (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. *Cancer Res* 50: 717-721.
8. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 98: 10869-10874.
9. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A* 100: 8418-8423.
10. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, et al. (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. *J Pathol* 203: 661-671.
11. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res* 10: 5367-5374.
12. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, et al. (1985) Measurement of protein using bicinchoninic acid. *Anal Biochem* 150: 76-85.